Literature DB >> 20936843

Lagunamides A and B: cytotoxic and antimalarial cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula.

Ashootosh Tripathi1, Jonathan Puddick, Michèle R Prinsep, Matthias Rottmann, Lik Tong Tan.   

Abstract

Lagunamides A (1) and B (2) are new cyclic depsipeptides isolated from the marine cyanobacterium Lyngbya majuscula obtained from Pulau Hantu Besar, Singapore. The planar structural characterization of these molecules was achieved by extensive spectroscopic analysis, including 2D NMR experiments. In addition to Marfey's method and (3)J(H-H) coupling constant values, a modified method based on Mosher's reagents and analysis using LC-MS was deployed for the determination of the absolute configuration. Lagunamides A and B displayed significant antimalarial properties, with IC(50) values of 0.19 and 0.91 μM, respectively, when tested against Plasmodium falciparum. Lagunamides A and B also possessed potent cytotoxic activity against P388 murine leukemia cell lines, with IC(50) values of 6.4 and 20.5 nM, respectively. Furthermore, these cyanobacterial compounds exhibited moderate antiswarming activities when tested against Pseudomonas aeruginosa PA01.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20936843     DOI: 10.1021/np100442x

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  24 in total

Review 1.  Biological targets and mechanisms of action of natural products from marine cyanobacteria.

Authors:  Lilibeth A Salvador-Reyes; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2015-03       Impact factor: 13.423

2.  A new peptide isolated from a marine derived Streptomyces bacillaris.

Authors:  Youcai Hu; John B MacMillan
Journal:  Nat Prod Commun       Date:  2012-02       Impact factor: 0.986

Review 3.  Marine natural product peptides with therapeutic potential: Chemistry, biosynthesis, and pharmacology.

Authors:  Vedanjali Gogineni; Mark T Hamann
Journal:  Biochim Biophys Acta Gen Subj       Date:  2017-08-24       Impact factor: 3.770

Review 4.  Antiplasmodial natural products: an update.

Authors:  Nasir Tajuddeen; Fanie R Van Heerden
Journal:  Malar J       Date:  2019-12-05       Impact factor: 2.979

5.  Structure-Activity Relationship Study on Odoamide: Insights into the Bioactivities of Aurilide-Family Hybrid Peptide-Polyketides.

Authors:  Masato Kaneda; Shinsaku Kawaguchi; Nobutaka Fujii; Hiroaki Ohno; Shinya Oishi
Journal:  ACS Med Chem Lett       Date:  2018-03-05       Impact factor: 4.345

Review 6.  Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies.

Authors:  Ricardo Ribeiro; Eugénia Pinto; Carla Fernandes; Emília Sousa
Journal:  Mar Drugs       Date:  2022-06-15       Impact factor: 6.085

Review 7.  Cyanobacteria-From the Oceans to the Potential Biotechnological and Biomedical Applications.

Authors:  Shaden A M Khalifa; Eslam S Shedid; Essa M Saied; Amir Reza Jassbi; Fatemeh H Jamebozorgi; Mostafa E Rateb; Ming Du; Mohamed M Abdel-Daim; Guo-Yin Kai; Montaser A M Al-Hammady; Jianbo Xiao; Zhiming Guo; Hesham R El-Seedi
Journal:  Mar Drugs       Date:  2021-04-24       Impact factor: 5.118

8.  Biochemical studies of the lagunamides, potent cytotoxic cyclic depsipeptides from the marine cyanobacterium Lyngbya majuscula.

Authors:  Ashootosh Tripathi; Wanru Fang; David Tai Leong; Lik Tong Tan
Journal:  Mar Drugs       Date:  2012-05-23       Impact factor: 6.085

Review 9.  Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis.

Authors:  Margarida Costa; João Costa-Rodrigues; Maria Helena Fernandes; Piedade Barros; Vitor Vasconcelos; Rosário Martins
Journal:  Mar Drugs       Date:  2012-09-28       Impact factor: 6.085

10.  Coibamide A induces mTOR-independent autophagy and cell death in human glioblastoma cells.

Authors:  Andrew M Hau; Jeffrey A Greenwood; Christiane V Löhr; Jeffrey D Serrill; Philip J Proteau; Ian G Ganley; Kerry L McPhail; Jane E Ishmael
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.